TRCT
NVCT icon

Tower Research Capital (TRC)’s Nuvectis Pharma NVCT Stock Holding History

Tower Research Capital (TRC)’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.5K Buy
5,762
+4,344
+306% +$37.2K ﹤0.01% 2845
2025
Q4 		$10.7K Sell
1,418
-2,431
-63% -$15.8K ﹤0.01% 3720
2025
Q3 		$23.2K Buy
+3,849
New +$26.5K ﹤0.01% 3175
2024
Q4 		– Sell
-588
Closed -$3.7K – 5906
2024
Q3 		$3.7K Sell
588
-5,408
-90% -$35.6K ﹤0.01% 4792
2024
Q2 		$38K Buy
5,996
+5,145
+605% +$35K ﹤0.01% 3306
2024
Q1 		$6.98K Sell
851
-427
-33% -$3.63K ﹤0.01% 4284
2023
Q4 		$10.7K Sell
1,278
-6,004
-82% -$53.5K ﹤0.01% 4216
2023
Q3 		$93.9K Buy
7,282
+6,739
+1,241% +$97.6K ﹤0.01% 2026
2023
Q2 		$8.67K Buy
543
+293
+117% +$4.68K ﹤0.01% 4389
2023
Q1 		$3K Sell
250
-1,109
-82% -$11.2K ﹤0.01% 5220
2022
Q4 		$10K Sell
1,359
-2,693
-66% -$19.3K ﹤0.01% 4041
2022
Q3 		$29K Buy
4,052
+2,773
+217% +$25.8K ﹤0.01% 3629
2022
Q2 		$14K Sell
1,279
-471
-27% -$5.82K ﹤0.01% 4153
2022
Q1 		$13K Buy
+1,750
New +$12.2K ﹤0.01% 3990

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tower Research Capital (TRC)'s NVCT Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Nuvectis Pharma (NVCT) stake by 306% in Q1 2026, buying an estimated $37.2K and bringing the position to 5,762 shares worth $44.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2845.

Tower Research Capital (TRC) first reported a position in NVCT in Q1 2022 and has held it in 14 quarters since. The position peaked at $93.9K in Q3 2023. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Tower Research Capital (TRC) held 5,762 shares of Nuvectis Pharma worth $44.5K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,344 Nuvectis Pharma shares in Q1 2026, an estimated $37.2K.
  • Nuvectis Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2845 holding.
  • Tower Research Capital (TRC) first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Nuvectis Pharma position peaked at $93.9K in Q3 2023.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.